JIUYUAN GENE (02566) surged over 7% following its earnings release. As of press time, the stock was up 7.02% to HK$15.4, with turnover reaching HK$10.2428 million.

On August 19, JIUYUAN GENE announced its interim results for the six months ended June 30, 2025. The group recorded revenue of RMB 639 million, representing a 9.05% year-on-year decline. Gross profit stood at RMB 525 million, down 2.84% compared to the same period last year. Net profit attributable to shareholders of the parent company reached RMB 90.174 million, declining 14.4% year-on-year, with earnings per share of RMB 0.37.

As of June 30, 2025, the company's total revenue decreased 9.1% year-on-year, while profit for the period fell 14.4% compared to the previous year. The slight decline in total revenue during the first half was primarily attributed to a combination of internal and external factors.

During the reporting period, the company's orthopedic product sales volume increased by over 10% year-on-year, with hospital penetration rates continuing to improve. Focusing on the company's full-year operational objectives, management is implementing differentiated commercial policies centered on stabilizing existing markets and cultivating incremental markets, aiming to achieve steady growth in full-year business revenue.